CONCERT's over: Pfizer and Medivation drop Alzheimer's candidate Dimebon
This article was originally published in Scrip
Executive Summary
Pfizer and Medivation have dropped all further development of Dimebon (latrepirdine) after it failed to reach the two primary endpoints in the Phase III CONCERT trial in Alzheimer's disease. There had once been high hopes for the candidate, but disappointing results from earlier studies in Alzheimer's and Huntington's disease meant that this result had been widely anticipated.